PMC:7546122 / 3156-3422 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15","span":{"begin":9,"end":17},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"To date, antibody binding assays have shown some cross-reactivity between different HCoVs and SARS-CoV-2; however, functional and therefore clinically more relevant virus neutralization assays have shown no or only very low levels of cross-reactive antibodies [6–8]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T17","span":{"begin":94,"end":102},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"To date, antibody binding assays have shown some cross-reactivity between different HCoVs and SARS-CoV-2; however, functional and therefore clinically more relevant virus neutralization assays have shown no or only very low levels of cross-reactive antibodies [6–8]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T29","span":{"begin":165,"end":170},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"To date, antibody binding assays have shown some cross-reactivity between different HCoVs and SARS-CoV-2; however, functional and therefore clinically more relevant virus neutralization assays have shown no or only very low levels of cross-reactive antibodies [6–8]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":266},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To date, antibody binding assays have shown some cross-reactivity between different HCoVs and SARS-CoV-2; however, functional and therefore clinically more relevant virus neutralization assays have shown no or only very low levels of cross-reactive antibodies [6–8]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"82","span":{"begin":94,"end":104},"obj":"Species"}],"attributes":[{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To date, antibody binding assays have shown some cross-reactivity between different HCoVs and SARS-CoV-2; however, functional and therefore clinically more relevant virus neutralization assays have shown no or only very low levels of cross-reactive antibodies [6–8]."}